ISBT 2017 – Copenhagen

Banniere horizontale ISBT 2017

We are pleased to invite you to our Symposium at the ISBT 2017 in Copenhagen

Join us Tuesday June 20, 2017 from 12 to 1.30pm, at room C14

Macopharma announce the publication of the first European, Prospective, Non-Interventional Study, of THERAFLEX Methylene Blue Plasma 

Tourcoing – March 29, 2017 — Macopharma today announced the publication of the manuscript related to the European prospective, non-interventional study, of THERAFLEX Methylene Blue Plasma, in Vox Sanguinis (DOI: 10.1111/vox.12510), which was carried out in collaboration with the SynteractHCR international CRO (Contract Research Organization), between May 2013 and April 2015.

The aim of this post-market surveillance study was to collect, during a period of at least one year, all adverse events that might be related to MB-treated plasma transfusions in seven key European hospitals of Belgium, United Kingdom (UK), Spain, and Greece, where MB-treated plasma is in routine use.

In this study, a total of 19,315 transfused units of MB plasma (3,780 transfusions for 3,005 recipients) were monitored. This number may be considered sufficiently robust to determine the safety of MB Plasma solidly. The incidence of serious Adverse Transfusion Reactions (ATRs) was 1 per 19,315 transfused units of MB plasma, which is similar to the incidence for untreated fresh frozen plasma reported by the French National Authority, ANSM. There were no ATRs reported in Greece where 9,241 units of MB plasma were transfused, nor in the UK where 434 units were transfused during the observation period.

“We are very pleased with the outcome of this trial; this prospective study confirms that Methylene Blue Plasma is a very safe product in routine use” Macopharma Medical Director Dr Ignacio Alvarez, said. “We are also very satisfied about the great collaboration we had with SynteractHCR.”

 

About Macopharma

Macopharma SA (“Macopharma”) (www.macopharma.com) is an innovator in global healthcare with expertise in the fields of transfusion and infusion. The company has become the largest supplier of in-line leucodepletion filtration sets in Europe. It is expanding its efforts in the fields of respiratory masks and cellular therapy by developing products for cell expansion, in addition to cell/organ processing and freezing. Headquartered in the Lille metropolitan area (France), Macopharma has four manufacturing facilities in Europe and its products are sold into more than 90 countries worldwide. One of Macopharma’s aims is to provide a comprehensive range for the pathogen reduction of infectious agents in plasma, platelets and red cells. This is aligned with Macopharma’s product development strategy of the continuous quest, through partnerships, for improved safety, efficacy, and quality of transfusion, infusion, masks and cellular therapy.

 

About THERAFLEX MB-Plasma

The THERAFLEX MB-Plasma System has a Class III CE Mark (available for sale in countries where the CE mark is accepted) and is not currently available for sale in the United States. It is a user-friendly in-house treatment for single units of plasma. The GMP-conforming procedure is adapted for the inactivation of FFP from aphaeresis or whole blood plasma. The MB-plasma system uses a combination of a membrane filter Plasmaflex PLAS4, (which removes residual leucocytes, red cells, platelets and aggregates, intra-cellular viruses and minimises the amount of microvesicles and microparticles), a dry Methylene Blue pill, visible light, and a Blueflex Methylene Blue removal filter.

See http://blood-safety.macopharma.com/ for more information.

About SynteractHCR

SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and in more than 50 countries, offering expertise across multiple therapeutic areas and with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy and ICD+ approach, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data so clients get to decision points faster.

See www.SynteractHCR.com, for more information.